(C) Wolf G Kroner 2009 - Daniel VasellaAdhering to Values Pays Off

January 2009. Presenting financial results 2008 Novartis’ management board outlines its strategy, and comments on competitors. Largely overlooked are the donation programs, its impact on the firm, and opportunities in emerging pharmaceutical markets.



If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 2 pages
- Includes key Financials 2008

Full Company License enquire here

Back to section

Related Editorial Articles

Pharma Boost for Red Cross/Red Crescent
- Community Disease Prevention Programme

Roche Ethiopia: Build-up of an emerging market

WHO ECEH taps major donation and streamlines European operations

Preparing for Another Level of Innovation
Mark Fishman, President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis on stem cell patents and technology acquisitions

Novartis counter-moves Vetoquinol, Virbac, and others in animal health
Editor's Note about Okapi Life Sciences PR